Larry L. Wood Sells 25,000 Shares of Edwards Lifesciences Co. (NYSE:EW) Stock

Edwards Lifesciences Co. (NYSE:EW) insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Edwards Lifesciences Trading Down 1.4 %

NYSE:EW opened at $65.75 on Thursday. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The firm’s fifty day moving average is $67.75 and its 200-day moving average is $77.18. The firm has a market cap of $39.61 billion, a P/E ratio of 9.49, a P/E/G ratio of 3.80 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 22.56%. The business had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter in the prior year, the firm posted $0.59 earnings per share. The business’s quarterly revenue was up 8.9% compared to the same quarter last year. Equities analysts expect that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on EW shares. Evercore ISI decreased their price target on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Canaccord Genuity Group lowered their target price on Edwards Lifesciences from $66.00 to $63.00 and set a “hold” rating for the company in a research note on Friday, October 25th. Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Finally, Oppenheimer reissued an “outperform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Seventeen analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $75.67.

Institutional Investors Weigh In On Edwards Lifesciences

A number of hedge funds have recently added to or reduced their stakes in EW. Empowered Funds LLC boosted its holdings in Edwards Lifesciences by 151.2% in the first quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company’s stock worth $1,923,000 after acquiring an additional 12,112 shares in the last quarter. Cetera Advisors LLC grew its position in Edwards Lifesciences by 175.1% in the 1st quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock valued at $3,640,000 after purchasing an additional 24,242 shares during the period. BDF Gestion bought a new stake in Edwards Lifesciences during the 2nd quarter valued at $5,148,000. Tidal Investments LLC raised its holdings in Edwards Lifesciences by 54.7% during the first quarter. Tidal Investments LLC now owns 30,245 shares of the medical research company’s stock worth $2,890,000 after buying an additional 10,700 shares during the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Edwards Lifesciences by 236.4% in the first quarter. SG Americas Securities LLC now owns 97,554 shares of the medical research company’s stock valued at $9,322,000 after buying an additional 68,556 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.